XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover Page - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Mar. 20, 2024
Jun. 30, 2023
Document Information [Line Items]      
Document Type 10-K/A    
Amendment Flag true    
Document Period End Date Dec. 31, 2023    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Entity Registrant Name AURA BIOSCIENCES, INC.    
Entity Central Index Key 0001501796    
Entity File Number 001-40971    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 32-0271970    
Entity Address, Address Line One 80 Guest Street    
Entity Address, City or Town Boston    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02135    
City Area Code 617    
Local Phone Number 500-8864    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Interactive Data Current Yes    
Entity Current Reporting Status Yes    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Title of 12(b) Security Common Stock, par value $0.00001 per share    
Trading Symbol AURA    
Security Exchange Name NASDAQ    
Document Annual Report true    
Document Transition Report false    
Entity Common Stock, Shares Outstanding   49,504,405  
Auditor Name Ernst & Young LLP    
Auditor Location Boston Massachusetts    
Auditor Firm ID 42    
Entity Public Float     $ 224.6
Amendment Description This Amendment No. 1 to Form 10-K (this “Amendment”) amends the Annual Report on Form 10-K for the year ended December 31, 2023 originally filed on March 27, 2024 (the “Original Report”) by Aura Biosciences, Inc., or the Company or Aura. The sole purpose of this Amendment is (a) to amend each of (1) Part III, Item 11 “Executive Compensation”, (2) Part III, Item 12 “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” and (3) Part III, Item 13 “Certain Relationships and Related Transactions, and Director Independence” of the Original Report, in each case, to update the disclosure for the Company’s named executive officers to include J. Jill Hopkins, M.D. and to remove Cadmus C. Rich, M.D. as a named executive officer, and (b) to amend Part III, Item 11 “Executive Compensation” of the Original Report to correct the calculation of the value of option awards to be in accordance with FASB Accounting Standards Codification Topic 718. Also included in this Amendment are (i) the signature page, (ii) certifications required of the principal executive officer and principal financial officer under Section 302 of the Sarbanes-Oxley Act of 2002 and (iii) Item 15, which has been restated in its entirety as set forth below to include the additional certifications and other exhibits. Because no financial statements are contained within this Amendment, the Company is not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Except as set forth in this Amendment, no other changes are made to the Original Report. Unless expressly stated, this Amendment does not reflect events occurring after the filing of the Original Report, nor does it modify or update in any way the disclosures contained in the Original Report, which speak as of the date of the Original Report. Accordingly, this Amendment should be read in conjunction with the Original Report and the Company’s other SEC filings subsequent to the filing of the Original Report.